Dr. Tewari on the Trial Design With Cemiplimab in Cervical Cancer

Video

Krishnansu Tewari, MD, associate professor, Division of Gynecologic Oncology, University of California, Irvine, discusses the trial design with cemiplimab (Libtayo) in recurrent or metastatic cervical cancer.

Krishnansu Tewari, MD, associate professor, Division of Gynecologic Oncology, University of California, Irvine, discusses the trial design with cemiplimab (Libtayo) in recurrent or metastatic cervical cancer.

The GOG 3016/ENGOT-cx9 is a randomized, phase III trial that is examining the use of cemiplimab, an anti—PD-1 agent, versus investigator's choice chemotherapy in patients with recurrent or metastatic cervical cancer. Investigators are hoping to accrue approximately 450 patients across 8 different countries.

Patients do not have to be PD-1/PD-L1—positive to be eligible for the trial, though it is being tested for, notes Tewari. If the study is positive, it will need to be reviewed by the FDA. The trial is being conducted in partnership with Regeneron, the manufacturer of the anti–PD-1 agent. Investigators are hoping that if the trial reports positive findings, it will approved by the FDA as a second-line therapy for patients with recurrent and metastatic cancer who have either progressed on platinum or platinum plus bevacizumab (Avastin).

In September 2018, the FDA approved the PD-1 inhibitor for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or patients with locally advanced CSCC who are not candidates for curative surgery or curative radiation.

Related Videos
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD
Saad J. Kenderian, MB, CHB, consultant, Division of Hematology, Department of Internal Medicine, Department of Immunology, Department of Molecular Medicine, assistant professor, oncology, immunology, medicine, Mayo Clinic
Mary-Ellen Taplin, MD